What Is Prelude Therapeutics Incorporat (PRLD) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Prelude Therapeutics Incorporat's intrinsic value is estimated at $1.48. Trading at its current price of $4.46, the valuation engine raises significant caution: 8 of 9 models flag downside risk, projecting an average implied return of -66.8%. The most optimistic model, PWERM, places fair value at $4.36 (-2.1%), while Sentiment SOTP — the most conservative — estimates $0.20 (-95.4%). This +93.3% gap reflects genuine analytical uncertainty about Prelude Therapeutics Incorporat's intrinsic worth.
What Do the Models Say About PRLD?
9 of 13 models are currently active for PRLD. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates PRLD's intrinsic value at $1.22, implying -72.6% downside from the current price. See which stocks rank higher →
How Does PRLD Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PRLD ranks #185 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to pharmaceutical industry businesses. For Prelude Therapeutics Incorporat, metrics like pipeline depth and stage distribution provide important context that general-purpose valuation models may underweight.
Is PRLD a Value Trap?
CirclFi's Value Trap algorithm assigns PRLD a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Prelude Therapeutics Incorporat. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Prelude Therapeutics Incorporat scores 5.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +93.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PRLD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PRLD's 9 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad